---
title: "National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298730316.md"
description: "National Beverage Corp (FIZZ) shares fell 3.5% in pre-market trading after reporting Q1 earnings of $0.50 per share and sales of $330.6 million, both missing analyst estimates. The stock joined other major movers lower, including Zumiez (ZUMZ), which dropped 15.7% on disappointing results, and Adobe (ADBE), which declined 3.1% despite beating expectations. Other declining stocks included Wealthfront, Resolution Minerals, Backblaze, Elevra Lithium, Arcturus Therapeutics, and Waterdrop."
datetime: "2026-09-11T12:04:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298730316.md)
  - [en](https://longbridge.com/en/news/298730316.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298730316.md)
generator: "portal-rs"
---

# National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 250 points on Friday.

Shares of **National Beverage Corp** (NASDAQ:FIZZ) fell in pre-market trading following downbeat first-quarter results.

National Beverage reported quarterly earnings of 50 cents per share which missed the analyst consensus estimate of 59 cents per share. The company reported quarterly sales of $330.662 million which missed the analyst consensus estimate of $342.080 million.

National Beverage shares dipped 3.5% to $29.83 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

-   **Zumiez Inc** (NASDAQ:ZUMZ) fell 15.7% to $14.07 in pre-market trading after the company reported worse-than-expected second-quarter financial results.
-   **Wealthfront Corp** (NASDAQ:WLTH) shares dipped 6.6% to $10.16 in pre-market trading. Wealthfront shares jumped 15% on Thursday after the company reported better-than-expected second-quarter financial results.
-   **Resolution Minerals Ltd** (NASDAQ:RML) shares fell 5.5% to $8.06 in pre-market trading after dipping 26% on Thursday..
-   **Backblaze Inc** (NASDAQ:BLZE) shares declined 4.5% to $11.76 in pre-market trading after dropping 7% on Thursday.
-   **Elevra Lithium Limited** (NASDAQ:ELVR) fell 3.7% to $51.46 in pre-market trading after dipping 9% on Thursday.
-   **Arcturus Therapeutics Holdings Inc** (NASDAQ:ARCT) fell 3.2% to $13.54 in pre-market trading after dipping 5% on Thursday.
-   **Adobe Inc** (NASDAQ:ADBE) fell 3.1% to $241.01 in pre-market trading. Adobe posted better-than-expected third-quarter fiscal 2026 results.
-   **Waterdrop Inc – ADR** NYSE: WDH) fell 3% to $1.00 in pre-market trading. Waterdrop recently reported a year-over-year increase in second-quarter sales results.

*Photo via Shutterstock*

### Related Stocks

- [BLZE.US](https://longbridge.com/en/quote/BLZE.US.md)
- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [WLTH.US](https://longbridge.com/en/quote/WLTH.US.md)
- [WDH.US](https://longbridge.com/en/quote/WDH.US.md)
- [ADBE.US](https://longbridge.com/en/quote/ADBE.US.md)
- [RML.US](https://longbridge.com/en/quote/RML.US.md)
- [FIZZ.US](https://longbridge.com/en/quote/FIZZ.US.md)
- [ZUMZ.US](https://longbridge.com/en/quote/ZUMZ.US.md)
- [ADBG.US](https://longbridge.com/en/quote/ADBG.US.md)
- [ADBU.US](https://longbridge.com/en/quote/ADBU.US.md)

## Related News & Research

- [CHRISTOPHER ADAM ELLIS Takes a Bullish Stance: Acquires $134K In Zumiez Stock](https://longbridge.com/en/news/300455971.md)
- [Zumiez President International Adam Christopher Ellis acquires $134,000 in common shares](https://longbridge.com/en/news/300330180.md)
- [Adobe forecasts US holiday online sales at USD 275.1 billion, up 6.7% YoY](https://longbridge.com/en/news/300301356.md)
- [Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency](https://longbridge.com/en/news/299948643.md)
- [Arcturus raised to Buy at Citi after mid-stage trial data for liver disease drug](https://longbridge.com/en/news/300047686.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**